Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbCellera Biologics Inc. - Common Shares
(NQ:
ABCL
)
2.030
+0.020 (+1.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbCellera Biologics Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Why Array Technologies Shares Are Trading Sharply Higher; Here Are 28 Stocks Moving Premarket
November 09, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares jumped 32% to $1.65 in pre-market trading. NeuroBo reported closing of $32.3 million underwritten public offering including full exercise of...
Via
Benzinga
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call Transcript
November 08, 2022
ABCL earnings call for the period ending September 30, 2022.
Via
The Motley Fool
AbCellera Reports Q3 2022 Business Results
November 08, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Recap: AbCellera Biologics Q1 Earnings
May 10, 2022
AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
AbCellera to Present at Upcoming Investor Conferences in November
November 04, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
November 02, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
October 11, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
October 05, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
September 21, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
September 02, 2022
We're starting off the final trading day of the week with an overview of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
August 11, 2022
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Via
Benzinga
Coinbase, Trade Desk, H&R Block And Some Other Big Gainers From Wednesday
August 11, 2022
U.S. stocks closed higher on Wednesday following the release of inflation data. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
August 10, 2022
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.
Via
Benzinga
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session
August 10, 2022
Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380.
Via
Benzinga
AbCellera Reports Q2 2022 Business Results
August 09, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
August 03, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
July 27, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
July 12, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
June 29, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Biologics's Return On Capital Employed Insights
June 10, 2022
According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million...
Via
Benzinga
Cramer Shares His Thoughts On Stem, Marvell Technology And More
May 17, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing.
Via
Benzinga
What 4 Analyst Ratings Have To Say About AbCellera Biologics
May 11, 2022
Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
AbCellera Reports Q1 2022 Business Results
May 10, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
May 03, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022
April 26, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
3 Biotech Stocks Under $10 to Add to Your Buy List
April 26, 2022
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.
Via
InvestorPlace
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
April 12, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
April 08, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Full Year 2021 Business Results
February 24, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.